Industrial Purity Specifications for 5'-Deoxy-5-Fluorocytidine (CAS 66335-38-4)
- Target Assay: Pharmaceutical grade requires ≥99.0% purity via HPLC, exceeding standard research grades of 94-98%.
- Critical Impurities: Strict control of residual solvents, heavy metals, and unreacted nucleoside precursors is mandatory for GMP compliance.
- Supply Chain: Bulk procurement demands verified COA data and scalable manufacturing processes from a trusted global manufacturer.
In the landscape of nucleoside chemistry, 5'-Deoxy-5-fluorocytidine (CAS: 66335-38-4) represents a critical intermediate for the development of antiviral and antineoplastic agents. The introduction of a fluorine atom at the 5'-position significantly alters the metabolic stability and bioavailability of the molecule. However, for commercial-scale pharmaceutical production, research-grade specifications are insufficient. Industrial applications demand rigorous adherence to purity profiles that ensure downstream reaction yields and final drug safety. As a premier global manufacturer, NINGBO INNO PHARMCHEM CO.,LTD. emphasizes the distinction between laboratory-scale reagents and GMP-compliant intermediates.
Defining Industrial-Grade Purity Standards (≥99.0% HPLC)
Market analysis indicates a divergence in available specifications for 5'-Deoxy-5-fluoro Cytidine. While some suppliers offer materials with purity levels around 94% to 98%, these are typically suited for early-stage discovery rather than process chemistry. Industrial synthesis requires a minimum assay of 99.0% as determined by High-Performance Liquid Chromatography (HPLC). Impurities above 0.1% can act as chain terminators or catalyst poisons in subsequent coupling reactions, drastically reducing overall yield.
The molecular formula C9H12FN3O4 and molecular weight of 245.21 g/mol require precise analytical verification. Standard quality control involves reverse-phase HPLC with UV detection, typically at 260 nm. It is crucial to distinguish between area normalization and external standard methods. For bulk transactions, the external standard method provides a more accurate quantification of the active pharmaceutical ingredient (API) intermediate. When evaluating suppliers for industrial purity standards, buyers must request chromatograms that demonstrate the separation of the main peak from closely related analogs and degradation products.
Critical Quality Control Parameters for Pharmaceutical Intermediates
Beyond the primary assay, a comprehensive Certificate of Analysis (COA) must address physical and chemical contaminants. The manufacturing process for fluorinated nucleosides often involves hazardous reagents and organic solvents that must be removed to acceptable limits. Residual solvents such as DMF, DMSO, or methanol must comply with ICH Q3C guidelines. Furthermore, the physical appearance should be consistent, typically described as white to almost white powder, indicating proper crystallization and drying.
The following table outlines the comparative specifications between standard research chemicals and industrial-grade intermediates required for process scale-up:
| Parameter | Research Grade | Industrial Grade (GMP Ready) | Test Method |
|---|---|---|---|
| Purity (Assay) | ≥ 94% - 98% | ≥ 99.0% | HPLC (Area %) |
| Residue on Ignition | ≤ 1.0% | ≤ 0.1% | Gravimetric (USP <281>) |
| Loss on Drying (LOD) | ≤ 5.0% | ≤ 0.5% | Karl Fischer / Oven |
| Heavy Metals | Not Always Specified | ≤ 10 ppm | ICP-MS / USP <233> |
| Single Impurity | ≤ 2.0% | ≤ 0.1% | HPLC |
Attention to Loss on Drying (LOD) is particularly vital for nucleosides, as hygroscopicity can affect weighing accuracy during formulation. Industrial specifications typically demand LOD values below 0.5%, ensuring the material is anhydrous or contains a known, stable hydrate form. Heavy metal limits are non-negotiable for intermediates destined for human therapeutics, requiring sensitive detection methods like ICP-MS.
Interpreting COA Data: Assay, Residue on Ignition, and LOD
A robust COA serves as the contractual foundation for bulk procurement. It is not merely a statement of compliance but a technical document that validates the synthesis route efficiency. Buyers should scrutinize the batch number and manufacturing date to ensure stability. For 5'-Deoxy-5-fluorocytidine, stability data should confirm that the material does not degrade significantly under recommended storage conditions, typically cool and dry environments protected from light.
Residue on ignition tests indicate the level of inorganic contaminants, which often stem from catalysts used during fluorination or deprotection steps. A high residue value suggests inadequate purification, which can complicate downstream processing. Similarly, the assay value must be supported by raw chromatographic data. Reputable suppliers provide HPLC chromatograms alongside the COA to verify peak identity and resolution. This transparency is a hallmark of NINGBO INNO PHARMCHEM CO.,LTD., ensuring clients receive data-backed quality assurance.
Scalability and Bulk Procurement Considerations
Transitioning from gram-scale research to kilogram or ton-scale production introduces unique challenges. The bulk price of nucleoside intermediates is influenced by the complexity of the fluorination step and the cost of starting materials. However, cost efficiency should never compromise quality. Established manufacturers optimize the manufacturing process to reduce waste and improve yield without sacrificing purity profiles.
Lead times and packaging are also critical commercial factors. Industrial clients require packaging that ensures integrity during long-distance shipping, such as double-lined polyethylene bags within fiber drums. Supply chain reliability is paramount; interruptions can halt entire production lines. Therefore, partnering with a supplier capable of consistent batch-to-b reproducibility is essential. By maintaining strict control over the synthesis route and quality control parameters, leading chemical producers ensure that the intermediates meet the rigorous demands of the pharmaceutical industry.
Conclusion
Securing high-quality 5'-Deoxy-5-fluorocytidine requires a deep understanding of industrial specifications beyond basic catalog data. The difference between 98% and 99.5% purity can determine the success of a clinical trial material or commercial batch. By prioritizing verified COA data, strict impurity profiles, and scalable supply chains, pharmaceutical companies can mitigate risk and ensure product efficacy. For reliable bulk supply and technical support, industry leaders rely on established partners committed to excellence in fine chemical manufacturing.